These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37805957)

  • 1. Should emergency departments be prescribing buprenorphine/naloxone?
    Bhat C; Zworth M; Rosenberg H
    CJEM; 2023 Oct; 25(10):787-788. PubMed ID: 37805957
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments.
    Stone KD; Scott K; Holroyd BR; Lang E; Yee K; Taghizadeh N; Deol J; Dong K; Fanaeian J; Ghosh M; Low K; Ross M; Tanguay R; Faris P; Day N; McLane P
    CJEM; 2023 Jul; 25(7):598-607. PubMed ID: 37245202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.
    Hu T; Snider-Adler M; Nijmeh L; Pyle A
    CJEM; 2019 Jul; 21(4):492-498. PubMed ID: 31006398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in Emergency Department Naloxone and Buprenorphine Initiation.
    Papp J; Emerman C
    West J Emerg Med; 2023 Jun; 24(4):710-716. PubMed ID: 37527392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
    Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
    Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder.
    Savage T; Ross M
    CJEM; 2022 Jan; 24(1):44-49. PubMed ID: 34564838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
    Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
    Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
    Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
    J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-site intervention to improve emergency department care for patients who live with opioid use disorder: A quantitative evaluation.
    McLane P; Scott K; Suleman Z; Yee K; Holroyd BR; Dong K; Ghosh SM; Fanaeian J; Deol J; Biggs C; Lang E; ; Hair H; Ross M; Tanguay R; Olmstead A; Fisher A; Fielding S
    CJEM; 2020 Nov; 22(6):784-792. PubMed ID: 32924911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
    Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
    Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.